ストックスクリーナーアプリを入手
7.23
1.36%
-0.10
Athira Pharma Inc (ATHA) 最新ニュース
Quarterly Trades: How sustainable is Athira Pharma Inc. stock dividend payoutJuly 2025 PreEarnings & Accurate Buy Signal Notifications - ulpravda.ru
Athira Pharma (NASDAQ:ATHA) CEO Mark James Litton Sells 2,586 Shares - Defense World
Worthington, Athira Pharma general counsel, sells $6k in ATHA stock - Investing.com Canada
Athira Pharma CSO Church sells $6k in ATHA stock - Investing.com
Aug Analyst Calls: How 1CM Inc IQ70 stock performs during market turbulence2025 Retail Activity & Short-Term Trading Opportunity Alerts - moha.gov.vn
Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World
Athira Pharma Stock Rockets 92% With 5-Day Winning Streak - Trefis
Athira Pharma Licenses Lasofoxifene For Metastatic Breast Cancer, Secures $236 Million Funding - Voice Of HealthCare
Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment - MSN
Why retail investors favor Athira Pharma Inc. stockQuarterly Portfolio Review & Consistent Return Investment Signals - Улправда
How strong is Athira Pharma Inc. stock balance sheetMarket Sentiment Report & Weekly High Return Stock Opportunities - bolumsonucanavari.com
Can Athira Pharma Inc. stock beat analyst upgradesTrade Signal Summary & Precise Buy Zone Identification - Улправда
Does Athira Pharma Inc. stock trade at a discount to peersJuly 2025 Big Picture & Daily Volume Surge Signals - Улправда
Volume Summary: Why retail investors favor Athira Pharma Inc. stockJuly 2025 Technicals & AI Powered Market Entry Ideas - Улправда
Athira Pharma Inc. (ATHA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Mizuho maintains Neutral on Athira Pharma stock after transformative deals By Investing.com - Investing.com Canada
How analysts rate Athira Pharma Inc. stock todayTrade Risk Report & Daily Momentum Trading Reports - Bölüm Sonu Canavarı
Will Athira Pharma Inc. stock benefit from automationWeekly Stock Recap & Reliable Price Action Trade Plans - Улправда
Athira Pharma raises $90 million as Bothell firm shifts focus - The Business Journals
Athira Pharma shares surge after securing rights to phase 3 breast cancer therapy - MSN
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast CancerSlideshow (NASDAQ:ATHA) 2025-12-18 - Seeking Alpha
Finance Watch: Athira Licenses Breast Cancer Drug, Raises Cash To Develop It - Citeline News & Insights
Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels - Stock Titan
Athira Pharma, Inc. (ATHA) Stock: Rockets 68% After Phase 3 Lasofoxifene Deal and $90M Private Placement - parameter.io
Athira Pharma Inc.: Growth or Bubble? - StocksToTrade
Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition? - Sahm
Athira Pharma acquires rights to phase 3 breast cancer drug By Investing.com - Investing.com Nigeria
Athira Pharma stock shot up 60% today – what’s triggering the super rally? - MSN
Nasdaq Gains Over 200 Points; US Inflation Slows To 2.7% - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Athira Pharma, Inc. announced that it expects to receive $89.724073 million in funding - marketscreener.com
Athira Pharma announces license to develop, commercialize lasofoxifene - TipRanks
Athira Pharma (ATHA) Stock Explodes 73% Higher on Breakthrough Cancer Drug Deal - Blockonomi
Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally? - Asianet Newsable
Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug - Investing.com Nigeria
Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug By Investing.com - Investing.com South Africa
Is It Too Late to Buy Athira Pharma Inc. Stock? - timothysykes.com
Why Is Athira Pharma Stock (ATHA) Up Today? - TipRanks
Athira Pharma pivots to oncology with new licensing deal - TipRanks
Athira Pharma acquires rights to phase 3 breast cancer drug - Investing.com
Athira Pharma Signs Multiple Material Agreements - TradingView — Track All Markets
Athira Pharma Announces Exclusive License to Lasofoxifene - GlobeNewswire
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Can Athira Pharma Inc. stock sustain market leadership2025 Bull vs Bear & Verified Momentum Stock Ideas - Улправда
Athira Pharma Earnings Notes - Trefis
Contrasting Day One Biopharmaceuticals (NASDAQ:DAWN) & Athira Pharma (NASDAQ:ATHA) - Defense World
Entry Recap: Will Athira Pharma Inc stock outperform growth indexesJuly 2025 Update & Free Risk Controlled Daily Trade Plans - moha.gov.vn
Athira Pharma (ATHA) price target increased by 700.00% to 4.08 - MSN
How Athira Pharma Inc. stock trades before earningsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Will Athira Pharma Inc. stock outperform growth indexes2025 Market Overview & Accurate Buy Signal Alerts - Newser
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
What analysts say about Athira Pharma Inc stockIndustrial Stocks Review & Start Learning With Our Courses - earlytimes.in
5.77%
大文字化:
|
ボリューム (24 時間):